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Abstract IL-28B polymorphisms are predictors of response to
therapy in adults infected with hepatitis C. We do not know
whether they are markers of response to therapy in children and
adolescents. The aim of this study was to determine whether
single-nucleotide polymorphisms (SNPs) in the IL-28B gene
could influence the probability of response to therapy com-
pared with other known baseline prognostic factors and corre-
late with clinical findings in pediatric patients infected with
hepatitis C virus (HCV) genotypes 1 or 4. We determined three
SNPs of IL-28B (rs12979860, rs12980275, and rs8099917) in
82 patients with chronic HCV infection treated with pegylated
interferon alpha and ribavirin (peg-IFNα/RBV). Treatment
response and clinical data were analyzed. Overall, sustained
virological response (SVR) was achieved by 45 % of patients
infected with difficult-to-treat HCV genotypes 1 and 4. Except
for IL-28B polymorphisms, there was no association of SVR
with any other clinical data. IL-28B rs12979860 CC [odds ratio
(OR), 6.81; p=0.001] and rs8099917 TT (OR,3.14; p=0.013)
genotypes were associated with higher SVR rates. IL-28B
rs12980275 was not significantly associated with SVR (p=
0.058). Only the distribution between CC and CT–TT geno-
types of rs12979860 significantly differentiated patients
achieving early virological response (EVR) (OR,10.0;
p=0.011). Children with the rs12979860 CC genotype had
significantly higher baseline viral load compared with CT–TT
patients (p=0.010). In children and adolescents chronically
infected with HCV genotypes 1 and 4, IL-28B rs12979860
and rs8099917 polymorphisms were the only predictors of
response to peg-IFN/RBV.
Introduction
The prevalence of hepatitis C virus (HCV) in children in
developed countries ranges between 0.1 and 0.4 %, and is
generally lower than in adults. However, HCV is the most
common cause of chronic liver disease of infectious etiology
in children [1]. Although new, specifically targeted antiviral
drugs are on the horizon, the combined therapy of pegylated
interferon alpha (peg-IFNα) and ribavirin (RBV) is currently
approved as the standard treatment for children. Even though
most experts believe that the treatment is beneficial, due to
several factors associated with treating young patients chroni-
cally infected with HCV, there is little consensus on when or
how to optimally treat children with HCV infection [1–3].
According to recommendation from the European Medicines
Agency (EMA), children with difficult-to-treat HCV genotypes
1 or 4 should be treated for 48 weeks, with treatment discon-
tinued after 12 weeks if there has been no viral response. The
main aim of therapy is to achieve a sustained virological
response (SVR), which frequently determines the rate of ther-
apeutic success. Identifying predictors of response to current
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therapy, particularly in patients infected with genotypes 1 and
4, remains as one of the main objectives of the research.
The viral factors, including HCV genotype, baseline viral
load, and viral kinetics during treatment, as well as the
characteristics of the host, such as age, gender, liver fibrosis,
insulin resistance, and absence of adherence to therapy, have
been fully studied in predicting the response to treatment
[4–7]. Both host and viral factors are recognized to be
important but do not adequately explain the observed vari-
ation in response to interferon alpha-based therapy for
chronic HCV. Recent genome-wide association studies
(GWAS) have shown that human genetic variations (sin-
gle-nucleotide polymorphisms, SNPs) around the gene for
interleukin 28B (IL-28B) may explain differences in the
results of the treatment of adults chronically infected with
HCV and that they can be useful as therapy response
markers [8–11]. Among them, the most important ones seem
to be rs12979860, rs8099917, and rs12980275. Currently, a
large number of independent validations of the importance
of IL-28B variants related to HCV treatment response in
different populations of chronically infected adults is being
carried out. According to these studies, patients with geno-
types CC rs12979860, TT rs8099917, and AA 12980275 are
statistically more likely to achieve SVR compared to patients
bearing the Tallele of rs12979860 (TTand CT), the G allele of
rs8099917 (TG and GG), and the G allele of rs12980275 (AG
and GG). Additionally, it was reported that the favorable IL-
28B genotypes were independent strongest pretreatment pre-
dictors of treatment response in European patients [12]. The
population of children has not yet been widely evaluated in
order to determine the relationships between IL-28B poly-
morphisms and treatment response. Although the described
variations are independent, their effects on the final therapy
outcome may have a different strength in adults and children,
due to the different distribution of prognostic factors that may
affect the final results of the therapy, such as liver fibrosis,
which seems to increase with the age of the patient and/or with
the duration of the disease. Therefore, higher rates of efficacy
are being observed in pediatric patients in clinical practice.
In the presented study, we defined the relationship between
SNPs rs12979860, rs12980275, and rs8099917 and response to
peg-IFN and RBV combined therapy in children and adoles-
cents infected with HCV genotypes 1 and 4. This information is
important for better prediction of response to therapy, and could
allow for a better selection of patients for further treatment.
Materials and methods
Patients and clinical data
Overall, 82 chronic HCV patients of Caucasian ethnicity, both
children and adolescents infected with viral genotypes 1 or 4,
were included in the study. We retrospectively selected a
cohort of naïve patients under 18 years of age who were
treated with combined antiviral therapy with peg-IFNα-2a or
2b and RBV between the years 2006 and 2011 in one of the
Polish academic centers. Children whose medical records
allowed to obtain information on the clinical course of infec-
tion and the effectiveness of treatment were included in the
analyses. Patients underwent treatment under a standard pro-
tocol with peg-IFNα (Pegasys, PegIntron) and weight-based
RBV for 48 weeks. The exclusion criteria included hepatitis B
or human immunodeficiency virus (HIV) coinfection, coexis-
tent autoimmune liver diseases, hemochromatosis, or other
coexistent chronic liver diseases (Wilson’s disease). Blood
samples from these patients were used for genotyping.
The HCV genotype was determined using the INNO-LiPA
HCVassay (Innogenetics) and chronic infection was defined as
a detectable HCV RNA for at least 6 months. In assessing the
effectiveness of antiviral treatment, virological response criteria
were used. Baseline viral load and viral concentration at week
12 of treatment were measured by quantitative polymerase
chain reaction (PCR) assay using the COBAS AmpliPrep/
COBAS TaqMan HCV RNA Test (Roche Molecular
Diagnostics); sensitivity > 15 IU/ml, dynamic range of quanti-
fication 43–69,000,000 IU/ml. In order to determine the treat-
ment’s efficacy, in patients with a 48-week course of therapy,
HCVRNA levels were measured by qualitative PCR at the end
of treatment and 24 weeks after the completion of treatment.
The primary endpoint of the study was SVR, defined as unde-
tectable HCV RNA in serum 24 weeks after the completion of
therapy. The lack of response to therapy was defined as HCV
viral load decline less than 2 logs at week 12 during therapy or
detectable HCVRNA in serum at any other time during the 48-
week therapy. Relapse was defined as undetectable HCV RNA
in serum at the end of therapy, followed by detectable HCV
RNA after the completion of therapy. The secondary endpoint
was early virological response (EVR), defined as a reduction of
HCV RNA by at least 2 logs after the first 12 weeks of
treatment compared with baseline HCV RNA levels. Patients
who failed to achieve EVR were considered to be non-
responders, and their therapy was discontinued. EVR with
undetectable HCV RNA in serum was referred as a complete
EVR (cEVR). To carry out the analysis, we divided the patients
into two groups: SVR (including individuals who achieved
SVR) and non-response/relapse (NR/R) (with individuals who
were non-respondent or who had a relapse during therapy).
Liver histological analysis was carried out by only one
pathologist using the modified Scheuer scoring system (F0–
F4; A0–A4) on liver biopsies obtained no later than 18months
before therapy. Detailed results of the demographic character-
istics and other standard clinical data were obtained from
patients’ clinical documentation. The protocol was approved
by the Ethics Committee of Collegium Medicum, Nicolaus
Copernicus University, Bydgoszcz, Poland. Informed consent
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was provided in writing by the legal guardian of each patient
before treatment was initiated.
DNA extraction and IL-28B genotyping
In order to carry out the genotyping analysis, genomic DNA
was prepared by the extraction method using Igepal CA-630
detergent from peripheral blood samples collected in 0.5 M
EDTA tubes. Subsequent handling of the DNA, including
quality control and dilution to working concentrations, was
carried out in our own laboratory. The genotyping of SNPs
rs12979860, rs12980275, and rs8099917 was carried out by
polymerase chain reaction and restriction fragment length
polymorphism (PCR-RFLP). For rs12979860, the primer
sequences were: 5′-CGC TTATCG CAT ACG GCT AGG-3′
(sense) and 5′-AGG CTC AGG GTC AAT CAC AGA AG-3′
(antisense). For rs8099917, the oligonucleotide primers were:
5′-CAT CCC ACT TCT GGA ACA AAT C-3′ (sense) and 5′-
GTATCAACCCCACCT CAAATTATC-3′ (antisense). For
rs12980275, the primer sequences were: 5′-AAG AGG AGG
GAA GGA AGT TCT G-3′ (sense) and 5′-GGT CTG GTC
CTA GTG GTG TTT G-3′ (antisense). The PCR conditions
(20 μL) were: initial denaturation at 95 °C for 2 min, followed
by 35 cycles of denaturation at 95 °C for 30 s, annealing at
60 °C for 25 s, and extension at 72 °C for 40 s. The PCR
products for rs12979860, rs8099917, and rs12980275 were of
243, 400, and 293 base pairs, respectively.
In order to perform the RFLP assay for the rs12979860
genotype, 15 μL of amplicons were digested with 2 U of
BstUI restriction endonuclease (Fermentas) at 37 °C for 12 h.
BstUI digestion of allele CC yields fragments of 136, 82, and
25 base pairs, whereas DNA containing the allele TT polymor-
phism yields fragments of 161 and 82 base pairs. For the RFLP
assay for the rs8099917 genotype, 15 μL of amplicons were
digested with 1 U of BseMI restriction endonuclease
(Fermentas) at 55 °C for 12 h. BseMI digestion of allele TT
yields fragments of 400 base pairs, whereas DNA containing
the allele GG polymorphism yields fragments of 234 and 166
base pairs. For the RFLP assay for the rs12980275 genotype,
20 μL of amplicons were digested with 2 U of BseLI
restriction endonuclease (Fermentas) at 55 °C for 12 h.
BseLI digestion of allele AA yields fragments of 178
and 115 base pairs, whereas DNA containing the allele
GG polymorphism yields fragments of 148, 115, and 30
base pairs. Restriction digestion products for each were
separated on agarose gel stained with ethidium bromide
for visualization on a UV transilluminator.
To confirm the PCR-RFLP results, the rs12979860,
rs8099917, and rs12980275 SNPs were genotyped using the
ABI TaqMan SNP genotyping assays (Applied Biosystems)
and predesigned commercial genotyping assays (ABI assay
C_11710096_10). The real-time PCR reactions were per-
formed in 96-well microplates with the ABI Prism 7000
Sequence Detection System (Applied Biosystems). Allele
discrimination was achieved by fluorescence detection.
Statistical analyses
In this work, the patient characteristics are reported asmedians
(ranges) or absolute and relative frequencies, n (%), as appro-
priate. The genetic and clinical features [age, gender, liver
histopathology (Scheuer score), viral load before treatment,
serum levels of alanine aminotransferase (ALT), HCV geno-
type, and IL-28B SNP] were compared between patients
having SVR (34 responders) and those who did not respond
to peg-IFN plus ribavirin treatment or had a relapse after the
end of the treatment (48 relapsers/non-responders). To identify
factors predicting treatment response, we evaluated the statis-
tical significance in the univariate analysis of the relationships
between clinical characteristics and the response phenotype
(responder/non-responder). Continuous variables were com-
pared with Mann–Whitney U-tests (the distributions were not
parametric). The Pearson Chi-square or Fisher’s exact test,
where appropriate, were used for categorical variables. For all
these tests, two-tailed p-values were used and p-values<0.05
were considered to be statistically significant. Odds ratios
(ORs) and 95 % confidence intervals (CIs) were also calcu-
lated for association tests between the IL-28B polymorphisms
and the binary clinical variables. All statistical analyses were
performed with SPSS software version 20 for Windows.
Results
Clinical characteristics
A total of 82 patients chronically infected with HCV, 14
(17.1 %) children (4–11 years old) and 68 (82.9 %) adoles-
cents (12–17 years old), 34 (41.5 %) girls and 48 (58.5 %)
boys, were studied. The median age at the onset of therapy
was 15 years. This study recruited patients infected with
HCV genotypes 1 (59.8 %) or 4 (40.2 %). The demographic
and clinical characteristics of the examined patients, strati-
fied by HCV genotype, are presented in Table 1.
All patients’ initial viral load was determined and described
by the percentage of patients in each categorization of high and
low initial viral load. The two limits most common in the
literature, that is, 600,000 and 800,000 IU/ml, were adopted.
The median baseline HCV viral load of the entire group was
3.98×105. For this patient characteristic, the level of ALT and
GGTP activity prior to treatment was taken into account. Forty-
eight (58.5 %) patients had abnormal ALT serum levels and 14
(17.1 %) patients had abnormal GGTP serum levels. For all
patients, the median levels of ALT and GGTP was 36 and 60
UI/L, respectively (normal range GGTP <61 and <36 UI/L and
ALT <41 and < 31 UI/L for males and females, respectively).
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Table 1 Characteristics of patients treated with pegylated interferon (peg-IFN) and ribavirin (RBV)
Characteristic All patients Genotype 1 Genotype 4
n 82 49 (59.8 %) 33 (40.2 %)
Age at the end of treatment (years)
Median (range) 15 (4–17) 15 ( 4–17) 15 (10–17)
<12 14 (17.1 %) 11 (22.4 %) 3 (9.1 %)
Gender
Girls 34 (41.5 %) 18 (36.7 %) 16 (48.5 %)
Boys 48 (58.5 %) 31 (63.3 %) 17 (51.5 %)
Liver fibrosis (F) stage (Scheuer)
Available 78 46 32
F0 12 (15.4 %) 7 (15.2 %) 5 (15.6 %)
F1 43 (55.1 %) 26 (56.5 %) 17 (53.1 %)
F2 21 (26.9 %) 12 (26.1 %) 9 (28.1 %)
F3 2 (2.6 %) 1 (2.2 %) 1 (3.1 %)
F4 0 (0.0 %) 0 (0.0 %) 0 (0.0 %)
Liver activity (A) grade (Scheuer)
Available 78 46 32
A0 1 (1.3 %) 1 (2.2 %) 0 (0.0 %)
A1 34 (43.6 %) 21 (45.6 %) 13 (40.6 %)
A2 39 (50.0 %) 22 (47.8 %) 17 (53.1 %)
A3 3 (3.8 %) 1 (2.2 %) 2 (6.3 %)
A4 1 (1.3 %) 1 (2.2 %) 0 (0.0 %)
Baseline ALT (U/l)
Median (range) 36 (10–285) 36 (10–191) 39 (20–285)
Abnormal 48 (58.5 %) 26 (53.1 %) 22 (66.7 %)
Baseline GGTP (U/l)
Median (range) 25 (6–122) 22 (6–74) 29 (9–122)
Abnormal 14 (17.1 %) 6 (13.0 %) 8 (24.2 %)
Baseline viral load (IU/ml)
Median (range), ×105 3.98 (0.037–54.5) 5.4 (0.25–54.5) 2.9 (0.037–11.5)*
≥600,000 32 (39.0 %) 24 (49.0 %) 8 (24.2 %)**
≥800,000 19 (23.2 %) 15 (30.6 %) 4 (12.1 %)
After 12 weeks of treatment
EVR 56 (68.3 %) 37 (75.5 %) 19 (57.6 %)
cEVR 25 (30.5 %) 14 (28.6 %) 11 (33.3 %)
Final outcome
SVR 34 (41.5 %) 22 (44.9 %) 12 (36.4 %)
R 7 (8.5 %) 5 (10.2 %) 2 (6.1 %)
NR 41 (50.0 %) 22 (44.9 %) 19 (57.6 %)
rs12979860
CC/CT/TT 20.7 %/54.9 %/24.4 % 22.4 %/57.2 %/20.4 % 18.2 %/51.5 %/30.3 %
rs8099917
TT/TG/GG 42.7 %/50.0 %/7.3 % 38.8 %/55.1 %/6.1 % 48.5 %/42.4 %/9.1 %
rs12980275
AA/AG/GG 19.5 %/54.9 %/25.6 % 20.4 %/57.1 %/22.5 % 18.2 %/51.5 %/30.3 %
ALT alanine aminotransferase; GGTP gamma-glutamyl transpeptidase; EVR early virological response; cEVR complete EVR; SVR sustained virological
response;R relapse;NR no response; reference values, normal rangeGGTP<61 and <36UI/L andALT<41 and<31UI/L formales and females, respectively
Data are presented as frequency (%), unless otherwise indicated
*Mann–Whitney Ustatistic test p=0.012 and **Chi-squared test p=0.024 for the comparison of genotype 1-infected patients with
genotype 4-infected patients
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Pretreatment liver biopsy samples were assessed from 78
(95 %) patients. The liver biopsy data showed that most
patients had staging F1 (55.1 %) and F2 (26.9 %), as well as
grading A1 (43.6 %) and A2 (50.0 %) (modified Scheuer
score). None of these patients had cirrhosis. The groups of
HCV genotype 1-infected patients and HCV genotype 4-
infected patients were comparable with respect to gender, age
at the start of the treatment, median serum ALT and GGTP
concentration, and liver histology, but their baseline viral loads
were different. Patients with HCV genotype 1 had significantly
higher baseline viral loads than patients with genotype 4 (5.4×
105 vs. 2.9×105 for genotypes 1 and 4, respectively; p=0.012).
There were no differences among HCV genotypes in the dis-
tribution alleles of IL-28B polymorphisms.
Overall, 34 (41.5 %) patients achieved an SVR and, in 48
cases, there was a treatment failure [41 patients (50.0 %) were
non-responders and 7 (8.5 %) were relapsers]. In selected
subgroups for HCV genotypes 1 or 4, the treatment efficacy
was 44.9 and 36.4 %, respectively, and the observed differ-
ence was not statistically significant. HCV viral load decline
of less than 2 logs at week 12 during therapy affected 31.7 %
of patients, but was more frequently observed in patients
infected with HCV genotype 4 [14 (42.4 %)] compared to
HCV genotype 1 infection [12 (24.5 %)]. Among the 56
patients who achieved EVR, 34 (60.7 %) achieved SVR.
Sixty patients with cEVR achieved SVR.
The rapid virological response (RVR), defined as an
undetectable HCV RNA at week 4 after treatment initiation,
was available for 34 patients. Among them, HCV RNAwas
undetectable in five patients (14.7 %) (data not shown).
Clinical and demographical variables associated with SVR
At first, the association between the main clinical and demo-
graphical variables known to influence HCV viral clearance
and achievement of SVR was evaluated. Factors such as age,
gender, liver histology, and viral load were assessed for obtain-
ing SVR. As shown in Table 2, there were no statistically
significant differences in the baseline characteristics between
responders and non-responders, which may be related with the
poor cardinality of the study group. Despite the lack of statis-
tical significance, the median values of ALTand GGTP activity
were lower in patients achieving SVR. In contrast, in our study,
responders had a higher median baseline viral load than non-
responders. In addition, the categorization of viremia in terms
of 8×105IU/ml value showed the greatest variation between
analyzed groups, with a reduced rate in a group achieving SVR.
Relationship between treatment response and IL-28B gene
polymorphisms
Among our 82 treated patients, the genotypic frequency of
rs12979860 CC was 20.7 %, CT was 54.9 %, and TT was
24.4 %. The proportion for rs8099917 TT was 42.7 %, TG
50.0 %, and GG 7.3 %, and for rs12980275 AAwas 19.5 %,
AG 54.9 %, and GG 25.6 %. Univariate analysis (Table 2)
showed no relationship of response type with either age at
therapy, gender, baseline viral load, fibrosis, or viral geno-
type (1 vs. 4). In contrast, a significant relationship was
observed between response type and the IL-28B SNP geno-
type. The response to treatment depending on the genotypes
of IL-28B is shown in Table 3. The genotype distributions
for IL-28B rs12979860 and rs8099917 polymorphisms
were significantly different between responders and non-
responders (p=0.001 and p=0.013, respectively). In our
series, for rs12979860, the odds ratio of being a responder
for the CC genotype as compared to genotypes CT and TT
was 6.81 (95 % CI=1.98–23.42). The SVR was achieved in
76.5 % of patients with the genotype CC of rs12979860,
compared with 33.3 % in patients with the genotype CT and
30.0 % in patients with the genotype T/T. For rs8099917,
the OR of being a responder for the TT genotype as com-
pared to genotypes TG and GG was 3.14 (95 % CI=1.26–
7.85). The response rates were 57.1, 31.7, and 16.7 % for
genotypes TT, TG, and GG, respectively. In contrast, no
significant difference was found between the genotype dis-
tribution of rs12980275 and treatment outcome (p=0.058).
Despite the lack of statistical significance, response rates for
rs12980275 indicate the relationship of this marker with
SVR. The response rates were 62.5, 37.8, and 33.3 % for
genotypes AA, AG, and GG, respectively.
A relationship was observed between EVR and the IL-28B
SNP genotype. The distribution of genotypes CC and CT–TT
rs12979860 significantly divided the patients in terms of the
frequency of achieving EVR (OR=10.0; 95 % CI=1.25–
80.14). In contrast, no significant differencewas found between
TT/TG–GG rs8099917 and AA/AG–GG rs12980275 geno-
types among patients with and without EVR. Additionally,
achieving cEVRwas independent of the genotypes distribution
of all the analyzed IL-28B polymorphisms.
Association between baseline viral load and IL-28B gene
polymorphisms
Patient age, gender distribution, ALT, GGTP activity, and liver
fibrosis stage did not differ by SNP genotype in the analyzed
groups. Despite there being no significant differences between
the median baseline viral load and treatment response among
the analyzed groups, a significant relationship between the
median baseline viral load and IL-28B rs12979860 genotypes
was shown (Fig. 1). The median baseline viral load for patients
with genotype CC rs12979860 was 7.1×105 (6.3×104–5.4×
106) and for patients with genotype CT–TT, it was 2.9×105
(3.7×103–4.7×106) (p=0.010). Although the median viral
load was higher in patients with either the TT rs8099917 or
AA rs12980275 genotypes, compared with patients with the
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TG–GG rs8099917 or AG–GG rs12980275 genotypes, the
differences did not reach statistical significance (p=0.087 and
p=0.053, respectively). Moreover, the viral load was analyzed
as a categorical variable using known cut-off levels of 600,000
or 800,000 IU/ml (Table 4). For a cut-off of 600,000 IU/ml, we
showed that favorable genotypes of all the analyzed markers
were associated with high viral load (rs12979860: OR=5.40,
95 % CI=1.68–17.38, p=0.003; rs8099917: OR=2.50, 95 %
CI=1.00–6.21, p=0.047; rs12980275: OR=3.33, 95 % CI=
1.07–10.36, p=0.032). However ,this association was not ob-
served using a cut-off level of 800,000 IU/ml for all markers.
Discussion
This retrospective study was performed in a large unique
monocentric cohort of 82 pediatric patients infected with
difficult-to-treat HCV genotypes 1 and 4, who were treated
with peg-IFN and RBV. Up to now, the results of several trials
in children and adolescents with chronic hepatitis C using peg-
IFNα-2a or 2b in combination with RBV have been reported
[13–17]. As expected, based on adult studies, the rates of
virological response were significantly lower in patients
infected with HCV genotypes 1 and 4 than in patients infected
with other genotypes. According to these studies, SVR rates in
patients with HCV genotype 1 ranged from 40 to 60 %, and
the relapse rate was between 7.7 and 17 %. However, data
regarding the efficacy of peg-IFN and RBV for the treatment
of chronic hepatitis C in children and adolescents infected
with genotype 4 are limited because of the small size of test
groups [18, 19]. In fact, most trials were carried out in western
countries, where HCV genotype 1 is the predominant variant,
followed by genotypes 2 and 3, and genotype 4 is relatively
uncommon. In our study, among all the analyzed pediatric
patients, the achievement of SVR was 41.5 % (44.9 % and
36.4 % for genotypes 1 and 4, respectively). Therefore, the
Table 2 Relationship between
treatment response and clinical
and demographic variables
aNot tested due to
discontinuation of treatment in
patients who did
not achieve EVR
Characteristic SVR, n=34 (41.5 %) R/NR, n=48 (58.5 %) p-Value
Age at the end of treatment (years)
Median (range) 15.5 (4–17) 14 (5–17) 0.420
<12 5 (14.7 %) 9 (18.8 %) 0.632
Gender
Girls 15 (44.1 %) 19 (39.6 %) 0.681
Boys 19 (55.9 %) 29 (60.4 %)
Liver fibrosis (F) stage (Scheuer)
Available 32 46
F0–F1 17 (53.1 %) 28 (60.9 %) 0.529
F2–F4 15 (46.9 %) 18 (39.1 %)
Liver activity (A) grade (Scheuer)
Available 32 46
A0–A1 16 (50.0 %) 19 (41.3 %) 0.626
A2–A4 16 (50.0 %) 27 (58.7 %)
Baseline ALT (U/l)
Median (range) 33.5 (10–191) 42.5 (19–285) 0.087
Abnormal 18 (52.9 %) 30 (62.5 %)
Baseline GGTP (U/l)
Median (range) 22 (6–94) 27.5 (6–122) 0.158
Abnormal 4 (11.8 %) 10 (20.8 %)
HCV genotype
1 22 (64.7 %) 27 (56.3 %) 0.442
4 12 (35.3 %) 21 (43.7 %)
Baseline viral load (IU/ml)
Median (range), ×105 4.3 (0.037–30.2) 3.5 (0.25–54.5) 0.290
≥600,000 14 (41.2 %) 18 (37.5 %) 0.737
≥800,000 5 (14.7 %) 14 (29.2 %) 0.126
After 12 weeks of treatment
EVR 34 (100.0 %) 22 (45.8 %) –a
cEVR 20 (58.8 %) 5 (10.4 %) –a
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SVR rate reported in our study is comparable to those
obtained from prospective clinical trials of children and ado-
lescents with HCV genotype 1.
In this study, we determined the role of known determinants
eliminating HCV in response to treatment in children who
received combined treatment with peg-IFN and RBV. We
determined that age, gender, ALT or GGTP activity, and
histological findings from liver biopsy do not significantly
correlate with the SVR rate in combined therapy. Responders
showed similar median baseline ALTand GGTP activity com-
pared with non-responders, and patients with normal ALT or
GGTP values display the same SVR rate as those with abnor-
mal biochemistry prior to therapy. Patient age and gender do
not seem to influence response; however, the group of patients
<12 years old was relatively small. According to our study, the
results for age, gender, ALT, and liver histology were similar to
those reported in known studies among children who received
combined treatment with peg-IFN and RBV. In contrast, the
lack of the baseline viral load’s role in predicting SVR pre-
sented in this study is at odds with the data previously pub-
lished byWirth et al. for patients with HCV genotype 1. Wirth
et al. showed that 32 % with high viral load (>600,000 IU/ml)
and 73 % with low viral load (<600,000 IU/ml) achieved SVR
[17]. In a second study by Sokal et al. using a cut-off value of
500,000 IU/ml, 45 % of children with HCV RNA
>500,000 IU/ml and 62 % with HCV RNA <500,000 IU/ml
achieved SVR [16]. Moreover, we demonstrated no predictive
role when the viral load was analyzed as a categorical variable
using a cut-off level of 800,000 IU/ml. In a comparative
analysis of baseline characteristics, we observed significantly
lower baseline viral loads in patients with HCV genotype 4
than in patients with HCV genotype 1; however, the SVR rates
between these subgroups do not differ significantly. This ob-
servation confirms previously reported findings in adults [20].
Because of discontinued therapy in patients who did not
achieve EVR, this study did not assess the statistical signifi-
cance of EVR and cEVR on the SVR rate. According to trials,
among the adult naïve patient population, less than 5 % of
patients who failed to achieve an EVR ultimately achieved
SVR [21]. However, similarly to other reports [13, 17], our
Table 3 Role of interleukin 28B
(IL-28B) gene polymorphisms
on virological response
in children and adolescents
with hepatitis C virus (HCV)





IL-28B SNP OR (95 % CI) p-Value
CC rs12979860 (n=17) CT–TT rs12979860 (n=65)
EVR 16 (94.1 %) 40 (61.5 %) 10.00 (1.25–80.14) 0.011
cEVR 7 (41.2 %) 18 (27.7 %) 1.83 (0.60–5.54) 0.282
ETR 13 (76.5 %) 26 (40.0 %) 4.87 (1.43–16.61) 0.013
SVR 13 (76.5 %) 21 (32.3 %) 6.81 (1.98–23.42) 0.001
TT rs8099917 (n=35) TG–GG rs8099917 (n=47)
EVR 26 (74.3 %) 30 (63.8 %) 1.64 (0.62–4.29) 0.314
cEVR 13 (37.1 %) 12 (25.5 %) 1.72 (0.67–4.45) 0.259
ETR 20 (57.1 %) 19 (40.4 %) 1.97 (0.81–4.77) 0.134
SVR 20 (57.1 %) 14 (29.8 %) 3.14 (1.26–7.85) 0.013
AA rs12980275 (n=16) AG–GG rs12980275 (n=66)
EVR 14 (87.5 %) 42 (63.6 %) 4.00 (0.84–19.12) 0.066
cEVR 6 (37.5 %) 19 (28.8 %) 1.48 (0.47–4.66) 0.497
ETR 10 (62.5 %) 29 (43.9 %) 2.13 (0.69–6.54) 0.182
SVR 10 (62.5 %) 24 (36.4 %) 2.92 (0.94–9.03) 0.058















Fig. 1 The association of the interleukin 28B (IL-28B) single-
nucleotide polymorphism (SNP) with hepatitis C virus (HCV) baseline
viral load in chronic HCV patients. There were significant differences
in viral load between patients with rs12979860 genotype CC (median,
7.1×105 IU/ml; range, 6.3×104–5.4×106 IU/ml) and CT–TT (2.9×105
IU/ml; range, 3.7×103–4.7×106 IU/ml; p=0.010). Statistical analysis
was performed using a Mann–Whitney U-test
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study determined that the distribution of EVR and cEVR
stratified by SVR showed an association with the SVR rate.
To the best of our knowledge, this is a unique study that
specifically examines the genotype frequencies of IL-28B
rs12979860, rs8099917, and rs12980275 polymorphisms in
children and adolescents with chronic HCV-1/4 infection.
Interestingly, the distribution of genotypes differed compared
to the results of studies conducted in adult Caucasian popula-
tions [8, 9, 20, 22]. While in the European studies of the
Caucasian race nearly 40 % incidence of the CC genotype is
observed, the incidence rate for patients in the study popula-
tion did not exceed 30 %. The reduced frequency of favorable
genotypes rs12979860 CC, rs8099917 TT, and rs12980275
AA may be a result of the test group’s limited cardinality and
needs to be confirmed in studies on a larger group of patients.
However, in the only available study, published in abstract
form, carried out by Hierro et al. on 61 children of white-
Hispanic population from which 52/61 were infected with
genotypes 1 and 4, the distribution of IL-28B rs12979860
genotype was as follows: CC=14 (22.9 %), CT=35
(57.3 %), TT=12 (19.6 %) [23]. In our and Hierro et al.’s
study, it was demonstrated that the most commonly occurring
rs8099917 marker genotype was the heterozygotic variant
TG, in contrast to adult patients, where the favorable TT
genotype dominated. In fact, in several adult trials, it was
demonstrated that the favorable IL-28B genotypes increase
the chances of spontaneous elimination of the virus [9, 24]. In
a recent study, Ruiz-Extremera et al. analyzed the role of IL-
28B polymorphism in HCV vertical transmission (HCV-VT)
and in the spontaneous clearance of HCV among infected
infants [25]. They showed that rs12979860 plays no role in
HCV-VT, but the IL-28B CC child polymorphism is associ-
ated independently with the spontaneous clearance of HCV
genotype 1 among infected infants born to HCV-infected
mothers. It was found that the CC polymorphism is the only
predictor of HCV clearance in HCV genotype 1 in infants.
Additionally, Hierro et al. reported an increased frequency of
parenteral infection in children with the rs12979860 CC ge-
notype [23]. Unfortunately, the mode of HCV infection in the
examined patients was not determined in our study.
The main focus of this study was to determine the predic-
tive value of IL-28B SNP in treatment outcome in children
and adolescents infected with HCV genotypes 1 and 4. In this
study, the IL-28B rs12979860 CT and rs8099917 TG, but not
rs12980275 polymorphisms’ pivotal role in predicting the rate
of SVR in the analyzed group was demonstrated. We found
that children/adolescent’s IL-28B polymorphisms were the
only predictors of SVR in HCV genotypes 1 and 4. A partic-
ularly strong relationship between rs12979860 and the viral
clearance rate was observed. Additionally, only the IL-28B
rs12979860 polymorphism affects the earliest treatment mile-
stone, which is EVR. However, neither rs12979860 nor other
markers influence cEVR. These observations suggest that
viral eradication at week 12 of treatment in HCV genotypes
1 and 4 infection is partly influenced by IL-28B. The relation-
ship between the IL-28B SNP and SVR has not been widely
studied in pediatric patients. In the study by Hierro et al.
performed on children with chronic HCV genotypes 1, 2,
and 4, the investigators demonstrated that polymorphisms in
the IL-28B gene region rs12979860 and 8099917 were the
only predictors of response to peg-IFN/RBV, a finding similar
to ours. Moreover, similarly to Hierro et al.’s results, we
showed a significant association of the IL-28B rs12979860
CC genotype with higher baseline viral load, and, in contrast,
no significant association with lower levels of ALT.
Despite promising results, this study has some limita-
tions. First of all, this is a retrospective study. Secondly, it
takes into consideration not only the patients who completed
Table 4 Impact of IL-28B SNP
on high baseline viral load




Baseline viral load (IU/ml) IL-28B SNP OR (95 % CI) p-Value
CC rs12979860 CT–TT rs12979860
≥600,000 12 (37.5 %) 20 (62.5 %) 5.40 (1.68–17.38) 0.003
<600,000 5 (10.0 %) 45 (90.0 %)
≥800,000 5 (26.3 %) 14 (73.7 %) 1.52 (0.46–5.04) 0.493
<800,000 12 (19.0 %) 51 (81.0 %)
TT rs8099917 TG–GG rs8099917
≥600,000 18 (56.2 %) 14 (43.8 %) 2.50 (1.00–6.21) 0.047
<600,000 17 (34.0 %) 33 (66.0 %)
≥800,000 9 (47.4 %) 10 (52.6 %) 1.28 (0.46–3.59) 0.638
<800,000 26 (41.3 %) 37 (58.7 %)
AA rs12980275 AG–GG rs12980275
≥600,000 10 (31.2 %) 22 (68.8 %) 3.33 (1.07–10.36) 0.032
<600,000 6 (12.0 %) 44 (88.0 %)
≥800,000 5 (26.3 %) 11 (17.5 %) 1.69 (0.50–5.67) 0.509
<800,000 14 (73.7 %) 52 (82.5 %)
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the planned treatment period (48 weeks). Furthermore,
reports of adults treatment showed no difference in SVR
between peg-IFNα 2a and 2b [26]; therefore, we hypothe-
size the same relation in patients <18 years old because of an
absence of a comparison study at this point in time. In this
study, we did not determine certain baseline characteristics
that may help to better select candidates for therapy, such as
infection mode. Studies among children showed that treat-
ment was particularly effective in patients with parenterally
acquired infections [13, 27]. However, statistical signifi-
cance was not reached, probably due to the small number
of enrolled patients. A prospective controlled study will be
necessary in order to evaluate the influence of IL-28B poly-
morphisms on peg-IFN and RBV combined treatment in
children and adolescents with chronic hepatitis C.
In conclusion, this study demonstrated the role of IL-28B
in predicting the outcome of antiviral therapy in children and
adolescents chronically infected with difficult-to-treat HCV
genotypes. Thus, the determination of the IL-28B SNP, like in
adults, may be useful in clinical practice in enhancing the
correct prediction of SVR achievement in treating this group
of young patients.
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